About Biogen (NASDAQ:BIIB)
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Industry, Sector and Symbol
Trailing P/E Ratio22.8095637583893
Forward P/E Ratio10.93
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales4.69
Cash Flow$26.32 per share
Price / Cash10.33
Book Value$59.56 per share
Price / Book4.56
Net Income$2.54 billion
Return on Equity38.32%
Return on Assets20.72%
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings results on Thursday, January, 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $5.44 by $0.18. The biotechnology company had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. Biogen's quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.04 EPS. View Biogen's Earnings History.
When will Biogen make its next earnings announcement?
What guidance has Biogen issued on next quarter's earnings?
Biogen issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided EPS guidance of $24.20-25.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $24.13. The company issued revenue guidance of $12.7-13.0 billion, compared to the consensus revenue estimate of $12.68 billion.
Where is Biogen's stock going? Where will Biogen's stock price be in 2018?
28 analysts have issued 12-month price objectives for Biogen's stock. Their predictions range from $279.00 to $433.00. On average, they expect Biogen's share price to reach $369.42 in the next twelve months. View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
- 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
- 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
- 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Bristol-Myers Squibb (BMY), Sanofi (SNY), Gilead Sciences (GILD), Bayer (BAYRY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Celgene (CELG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Shire (SHPG), Illumina (ILMN), Regeneron Pharmaceuticals (REGN), Astellas Pharma (ALPMY), Actelion (ALIOF) and Alexion Pharmaceuticals (ALXN).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board (Age 68)
- Michel Vounatsos, Chief Executive Officer, Director (Age 55)
- Jeffrey D. Capello, Chief Financial Officer, Executive Vice President (Age 53)
- Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President (Age 49)
- Kenneth A. Di Pietro, Executive Vice President - Human Resources (Age 58)
- Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 60)
- Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development (Age 48)
- Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
- Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs (Age 54)
- Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations (Age 51)
Has Biogen been receiving favorable news coverage?
Headlines about BIIB stock have been trending somewhat positive on Thursday, Accern reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biogen earned a media sentiment score of 0.06 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Biogen's major shareholders?
Biogen's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.94%),
PRIMECAP MANAGEMENT COMPANY
(7.16%), Clearbridge Investments LLC (4.32%), Alliancebernstein L.P. (1.61%), Geode Capital Management LLC (1.16%) and Bank of New York Mellon Corp (1.13%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Jackson Square Partners LLC, Credit Agricole S A, BlackRock Inc., Teacher Retirement System of Texas and Clearbridge Investments LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Amundi Pioneer Asset Management Inc., Robeco Institutional Asset Management B.V., Smith Asset Management Group LP, Los Angeles Capital Management & Equity Research Inc., American Century Companies Inc., ADAMCAPITAL Gestao de Recursos Ltda. and Teachers Advisors LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $271.89.
How big of a company is Biogen?
Biogen has a market capitalization of $59.17 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $11.92 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (BIIB)MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biogen (NASDAQ:BIIB) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.71||2.72||2.75||2.54|
|Ratings Breakdown: ||0 Sell Rating(s)|
8 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
8 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
12 Hold Rating(s)
11 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$369.42||$368.30||$351.44||$329.27|
|Price Target Upside: ||35.87% upside||23.02% upside||8.97% upside||3.22% upside|
Biogen (NASDAQ:BIIB) Consensus Price Target History
Biogen (NASDAQ:BIIB) Analyst Ratings History
(Data available from 3/22/2016 forward)
Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart
Biogen (NASDAQ BIIB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/25/2018||Q4 2017||$5.44||$5.26||$3.08 billion||$3.31 billion||View||Listen|
|10/24/2017||Q3 2017||$5.70||$6.31||$3.05 billion||$3.08 billion||View||N/A|
|7/25/2017||Q2 2017||$4.36||$5.04||$2.81 billion||$3.08 billion||View||N/A|
|4/25/2017||Q1 2017||$4.97||$5.20||$2.73 billion||$2.81 billion||View||N/A|
|1/26/2017||Q416||$4.96||$5.04||$2.94 billion||$2.87 billion||View||N/A|
|10/26/2016||Q316||$4.97||$5.19||$2.91 billion||$2.96 billion||View||Listen|
|7/21/2016||Q216||$4.69||$5.21||$2.79 billion||$2.89 billion||View||Listen|
|4/21/2016||Q116||$4.47||$4.79||$2.75 billion||$2.73 billion||View||Listen|
|1/27/2016||Q415||$4.08||$4.50||$2.70 billion||$2.84 billion||View||Listen|
|10/21/2015||Q315||$3.80||$4.48||$2.65 billion||$2.39 billion||View||Listen|
|7/24/2015||Q215||$4.10||$4.22||$2.71 billion||$2.59 billion||View||Listen|
|4/24/2015||Q115||$3.91||$3.82||$2.66 billion||$2.56 billion||View||Listen|
|1/29/2015||Q414||$3.74||$4.09||$2.64 billion||$2.60 billion||View||Listen|
|10/22/2014||Q3||$3.22||$3.80||$2.48 billion||$2.50 billion||View||Listen|
|7/23/2014||Q214||$2.80||$3.49||$2.14 billion||$2.42 billion||View||Listen|
|4/23/2014||Q114||$2.56||$2.47||$2.00 billion||$2.10 billion||View||Listen|
|1/29/2014||Q413||$2.27||$2.34||$1.93 billion||$2.00 billion||View||Listen|
|10/28/2013||Q313||$2.10||$2.35||$1.78 billion||$1.83 billion||View||Listen|
|7/25/2013||Q2 2013||$1.93||$2.30||$1.62 billion||$1.70 billion||View||Listen|
|4/25/2013||Q1 2013||$1.63||$1.97||$1.41 billion||$1.40 billion||View||Listen|
|1/28/2013||Q4 2012||$1.46||$1.40||$1.38 billion||$1.40 billion||View||Listen|
Biogen (NASDAQ:BIIB) Earnings Estimates
2018 EPS Consensus Estimate: $24.85
2019 EPS Consensus Estimate: $26.76
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com
Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.90%
Biogen (NASDAQ BIIB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/27/2018||Alfred Sandrock||EVP||Sell||259||$290.83||$75,324.97||6,553|| |
|2/20/2018||Alfred Sandrock||EVP||Sell||743||$292.00||$216,956.00||6,553|| |
|2/15/2018||Alfred Sandrock||EVP||Sell||1,294||$298.85||$386,711.90||7,296|| |
|1/9/2018||Robert W Pangia||Director||Sell||5,832||$329.65||$1,922,518.80||23,539|| |
|12/29/2017||Michel Vounatsos||CEO||Buy||780||$320.55||$250,029.00|| |
|12/29/2017||Michel Vounatsos||CEO||Buy||780||$320.55||$250,029.00||4,879|| |
|11/29/2017||Alexander J Denner||Director||Buy||30,000||$317.36||$9,520,800.00||10,029|| |
|7/25/2017||Susan H Alexander||EVP||Sell||4,974||$290.01||$1,442,509.74||22,258|| |
|7/19/2017||Susan H Alexander||EVP||Sell||7,758||$285.00||$2,211,030.00||27,232|| |
|6/9/2017||Brian S Posner||Director||Sell||1,084||$256.31||$277,840.04||6,330|| |
|5/1/2017||Michel Vounatsos||CEO||Buy||1,402||$271.35||$380,432.70|| |
|4/27/2017||Alexander J. Denner||Director||Buy||73,858||$278.50||$20,569,453.00|| |
|4/25/2017||Paul J Clancy||VP||Sell||9,892||$290.00||$2,868,680.00||10,813|| |
|4/3/2017||Alfred Sandrock||CMO||Sell||1,981||$274.08||$542,952.48||7,060|| |
|3/13/2017||Paul J Clancy||VP||Sell||9,891||$291.55||$2,883,721.05||20,705|| |
|2/27/2017||Michel Vounatsos||CEO||Buy||1,333||$285.39||$380,424.87|| |
|1/9/2017||Robert W Pangia||Director||Sell||5,450||$295.39||$1,609,875.50||22,078|| |
|10/4/2016||Adriana Karaboutis||EVP||Sell||262||$311.94||$81,728.28||7,579|| |
|10/3/2016||Adriana Karaboutis||EVP||Sell||380||$313.00||$118,940.00||7,172|| |
|9/22/2016||Caroline Dorsa||Director||Sell||27,570||$314.00||$8,656,980.00||19,663|| |
|7/21/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00||54,779|| |
|6/6/2016||Adam Koppel||EVP||Sell||555||$290.00||$160,950.00||2,402|| |
|6/3/2016||George A Scangos||CEO||Sell||842||$290.00||$244,180.00||54,936|| |
|6/1/2016||George A Scangos||CEO||Sell||3,855||$289.74||$1,116,947.70||56,265|| |
|5/25/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00||59,633|| |
|5/2/2016||George A Scangos||CEO||Sell||487||$274.74||$133,798.38||59,790|| |
|4/6/2016||Adam Koppel||EVP||Sell||102||$275.00||$28,050.00||1,848|| |
|4/6/2016||George A Scangos||CEO||Sell||157||$280.00||$43,960.00||60,277|| |
|4/1/2016||George A Scangos||CEO||Sell||487||$258.83||$126,050.21||60,434|| |
|3/1/2016||George A Scangos||CEO||Sell||487||$261.37||$127,287.19||60,921|| |
|2/25/2016||Adriana Karaboutis||EVP||Sell||84||$261.90||$21,999.60||8,127|| |
|2/25/2016||Alfred Sandrock||CMO||Sell||183||$261.90||$47,927.70||7,990|| |
|2/17/2016||Alfred Sandrock||Chief Medical Officer||Sell||722||$256.16||$184,947.52||7,990|| |
|2/17/2016||George A Scangos||CEO||Sell||487||$256.16||$124,749.92||59,848|| |
|2/9/2016||Alfred Sandrock||Chief Medical Officer||Sell||852||$246.54||$210,052.08||7,740|| |
|12/4/2015||Alfred Sandrock||CMO||Sell||441||$277.00||$122,157.00||7,740|| |
|10/23/2015||Alexander J Denner||Director||Buy||310,000||$277.47||$86,015,700.00||7,890|| |
|7/27/2015||Stelios Papadopoulos||Director||Buy||10,000||$304.88||$3,048,800.00|| |
|6/19/2015||Douglas E Williams||EVP||Sell||3,841||$410.00||$1,574,810.00|| |
|6/1/2015||George A Scangos||CEO||Sell||1,362||$398.87||$543,260.94|| |
|4/1/2015||George A Scangos||CEO||Sell||1,362||$423.20||$576,398.40|| |
|3/25/2015||John Cox||EVP||Sell||12,010||$449.06||$5,393,210.60|| |
|3/20/2015||Eric K Rowinsky||Director||Sell||11,667||$475.00||$5,541,825.00|| |
|3/19/2015||Eric K Rowinsky||Director||Sell||2,333||$436.14||$1,017,514.62|| |
|3/17/2015||Eric K Rowinsky||Director||Sell||4,667||$425.45||$1,985,575.15|| |
|3/10/2015||Robert W Pangia||Director||Sell||3,625||$413.40||$1,498,575.00|| |
|3/2/2015||Alfred Sandrock||SVP||Sell||3,174||$409.49||$1,299,721.26|| |
|2/17/2015||Steven H Holtzman||EVP||Sell||2,128||$389.11||$828,026.08|| |
|2/10/2015||Alfred Sandrock||SVP||Sell||1,143||$398.11||$455,039.73|| |
|2/2/2015||Kenneth Dipietro||EVP||Sell||1,656||$389.03||$644,233.68|| |
|12/15/2014||Spyridon Artavanis-Tsakonas||SVP||Sell||1,981||$346.50||$686,416.50|| |
|12/2/2014||Steven H Holtzman||EVP||Sell||1,749||$335.65||$587,051.85|| |
|11/11/2014||Steven H Holtzman||EVP||Sell||1,750||$330.00||$577,500.00|| |
|11/3/2014||George A Scangos||CEO||Sell||1,128||$320.78||$361,839.84|| |
|10/1/2014||George A Scangos||CEO||Sell||1,127||$330.97||$373,003.19|| |
|10/1/2014||Steven H Holtzman||EVP||Sell||1,750||$330.97||$579,197.50|| |
|8/1/2014||George A Scangos||CEO||Sell||1,128||$332.93||$375,545.04|| |
|7/16/2014||George A Scangos||CEO||Sell||12,316||$312.37||$3,847,148.92|| |
|5/19/2014||Steven Holtzman||EVP||Sell||1,221||$289.15||$353,052.15||5,749|| |
|5/1/2014||George Scangos||CEO||Sell||2,123||$285.56||$606,243.88||24,019|| |
|4/17/2014||Steven Holtzman||EVP||Sell||1,221||$291.00||$355,311.00||6,970|| |
|4/1/2014||George Scangos||CEO||Sell||2,123||$308.42||$654,775.66||26,142|| |
|4/1/2014||Robert Pangia||Director||Sell||6,250||$308.42||$1,927,625.00||14,003|| |
|3/31/2014||Brian Posner||Director||Sell||3,000||$296.76||$890,280.00||6,435|| |
|3/20/2014||Caroline Dorsa||Director||Sell||10,000||$348.88||$3,488,800.00||14,468|| |
|3/19/2014||Douglas Williams||EVP||Sell||3,505||$352.29||$1,234,776.45||7,976|| |
|3/17/2014||Steven Holtzman||EVP||Sell||1,221||$334.83||$408,827.43||8,191|| |
|3/11/2014||Stuart Kingsley||EVP||Sell||8,428||$336.83||$2,838,803.24||3,511|| |
|3/3/2014||George Scangos||CEO||Sell||2,942||$335.79||$987,894.18||54,389|| |
|2/26/2014||Alfred Sandrock||SVP||Sell||1,048||$342.17||$358,594.16||21,407|| |
|2/18/2014||Steven Holtzman||EVP||Sell||1,222||$327.90||$400,693.80||9,412|| |
|2/13/2014||Kenneth Dipietro||EVP||Sell||1,290||$316.81||$408,684.90|| |
|2/11/2014||Alfred Sandrock||SVP||Sell||2,085||$314.31||$655,336.35||13,667|| |
|2/11/2014||George Scangos||CEO||Sell||2,456||$314.31||$771,945.36||52,961|| |
|2/4/2014||Kenneth Dipietro||EVP||Sell||1,655||$299.01||$494,861.55|| |
|1/21/2014||Eric Rowinsky||Director||Sell||2,020||$310.09||$626,381.80||10,440|| |
|1/15/2014||Lynn Schenk||Director||Sell||1,000||$297.48||$297,480.00||3,325|| |
|1/8/2014||William Young||Director||Sell||15,000||$285.11||$4,276,650.00||18,509|| |
|1/6/2014||Robert Pangia||Director||Sell||6,250||$278.03||$1,737,687.50||14,003|| |
|12/2/2013||Lynn Schenk||Director||Sell||1,000||$291.71||$291,710.00||3,325|| |
|11/22/2013||Raymond Pawlicki||SVP||Sell||4,000||$288.00||$1,152,000.00||8,710|| |
|11/1/2013||George A Scangos||CEO||Sell||2,239||$245.57||$549,831.23|| |
|11/1/2013||Lynn Schenk||Director||Sell||1,000||$245.00||$245,000.00|| |
|10/22/2013||Alfred Sandrock||SVP||Sell||15,030||$250.11||$3,759,153.30|| |
|9/18/2013||Paul Clancy||CFO||Sell||26,785||$245.00||$6,562,325.00||7,087|| |
|9/17/2013||Steven Holtzman||EVP||Sell||3,501||$238.98||$836,668.98||4,885|| |
|9/16/2013||Paul Clancy||CFO||Sell||99,030||$238.27||$23,595,878.10||7,087|| |
|9/16/2013||Raymond Pawlicki||SVP||Sell||4,000||$238.03||$952,120.00||8,710|| |
|9/3/2013||George Scangos||CEO||Sell||2,239||$214.40||$480,041.60||43,522|| |
|8/26/2013||Douglas Williams||EVP||Sell||4,368||$211.35||$923,176.80||4,571|| |
|8/1/2013||George A Scangos||CEO||Sell||2,239||$218.82||$489,937.98|| |
|7/16/2013||George A Scangos||CEO||Sell||2,239||$223.94||$501,401.66|| |
|6/14/2013||Alexander J Denner||Director||Sell||2,900||$212.00||$614,800.00|| |
|6/11/2013||Brian S Posner||Director||Sell||2,020||$219.62||$443,632.40|| |
|6/10/2013||Lynn Schenk||Director||Sell||2,000||$225.82||$451,640.00|| |
|6/3/2013||George A Scangos||CEO||Sell||1,598||$234.16||$374,187.68|| |
|6/3/2013||Stephen A Sherwin||Director||Sell||12,825||$233.26||$2,991,559.50|| |
|5/28/2013||Robert W Pangia||Director||Sell||5,900||$237.23||$1,399,657.00|| |
|12/27/2012||Alexander J Denner||Director||Sell||7,980||$148.62||$1,185,987.60|| |
Biogen (NASDAQ BIIB) News Headlines
Biogen (NASDAQ:BIIB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement
Biogen (NASDAQ BIIB) Stock Chart for Thursday, March, 22, 2018